Abstract

The participation rate in cancer clinical trials is low – 3% of patients with advanced cancer enroll in phase 1 clinical trials. Patients with refractory symptoms are potential candidates for trials of new interventions. While it is important that patients who do enroll in these studies understand the minimal chance they have of meaningful personal benefit from a phase 1 trial, it is also unfortunate if ‘fighters’ are missing the opportunity to participate in clinical trials that could provide them with further hope, a sense of completion of all possible treatments, and the knowledge that their efforts may benefit others. Oncologists and members of the cancer care team can help patients recognize if clinical trials are suitable for them. Importantly, oncologists can integrate attentive symptom management into their overall cancer care simultaneously with the clinical trial. This module presents an approach to structuring the communication about participation in phase 1 clinical trials based on the 7-steps presented in EPEC-O Module 7: Communicating Effectively.

Key words

Phase 1 trials, fighters, hope, false hope, clinical trials, palliative care research, conflict of interest

Objectives

After studying this module, oncologists and other members of the cancer care team will be able to:

- Describe the reasons why patients participate in clinical trials.
- Describe the opportunities for patients in phase 1 clinical trials.
- Discuss phase 1 clinical trials with patients and families using a 7-step protocol.

Clinical case on trigger tape

S.T. is a 42-year-old lawyer with pancreatic cancer initially treated with chemotherapy and radiotherapy. The tumor size remained stable until recently the CT scans show it is larger. He is more fatigued than usual but is still working. He has inquired about surgery and was deeply disappointed to not be a candidate. He has done internet searches and has inquired about a clinical trial. He is not ready to die. He is in the office today to be considered for a phase 1 clinical trial of a new agent.

Introduction

In the early twenty-first century, somewhat fewer than 1.5 million Americans are diagnosed with cancer and over half a million die of cancer each year.¹ Clinical trials present a further opportunity for patients and families to:
• Try an additional therapy, even though the potential for benefit to them may be very low.

• Know they’ve tried everything possible and reasonable to prolong the patient’s life.

• Give the patient and family further time to realize and adjust to their future.

• Provide a gift of knowledge to other patients who may benefit from their efforts.

It is estimated that 40-60,000 cancer patients will be enrolled in clinical research trials each year, and about 2-4,000 will be enrolled in Phase 1 studies. About half of these patients have advanced cancer. As a proportion of the total number of people living with cancer, these data indicate that < 1% of all cancer patients actually enroll in clinical trials and about 3% of those with advanced cancer enroll in phase 1 trials. Surveys suggest there are many reasons for this low participation rate: too few trials, restrictive eligibility criteria on the trials that are offered, physicians not offering eligible patients trials, and patients refusing enrollment in trials.

Why patients enroll in trials

Caution has surrounded clinical trials for people with serious illness. Many people have concerns that cancer patients, especially terminally ill cancer patients who have exhausted conventional therapeutic options, enroll in research only because they have therapeutic misconceptions, ie, ‘How could they sign up for a study with few or no prospects of benefits and many side effects unless they somehow had false hope that it would provide benefit?’

It appears that many cancer patients who sign up for research trials hope they will benefit personally. Joffe et al found that among cancer research participants:

• 70% agreed with the claim that ‘the treatment being researched in my clinical trial has been proven to be the best treatment for my type of cancer’

• 63% agreed with the claim that ‘compared with standard treatments for my type of cancer, my clinical trial does not carry any additional risks or discomfort.’

Similarly, Meropol et al reported that 77% of phase 1 trial participants hoped they would have a 50% or higher chance of benefit from the therapy.

These data indicate that most cancer patients believe their research interventions will be beneficial. But the situation is also more complex. Simultaneously with these responses, cancer research participants recognize that they might not personally benefit. For instance, in Joffe’s study:

• 75% of participants’ agreed that there may not be directive medical benefit to me from my participation in this clinical trial.

These responses seem contradictory and many have only commented on the interpretation that patients have misconceptions about research. An interpretation that is
true to the data also supports the view that participants are perfectly coherent and hold an understandably ambivalent perspective that works for their circumstances and dispositions. Patients recognize that there is only a small chance that they will benefit, while simultaneously they hope that they will benefit—they hope they will be among the few who will have tumor shrinkage or even cure. *Holding these two views—knowing that you are unlikely to benefit but hoping you will be among the few who do benefit—is characteristic of people who are ‘fighters,’ ie, not ready to give up, and ‘risk takers. Indeed, it has been termed the ‘gambler’s’ mentality.*

One patient who wrote of his rationale for joining a Phase 1 cancer study characterized this personality and world view in the following way:

“Most patients do not ask to participate in protocols but rather are content to either let the disease follow its natural course or adhere to advice of their health care providers (who in turn may be somewhat fatalistic). Patients who seek to participate in protocols are those who question the status quo and who are most eager to alter it….We who are struggling to escape cancer do not, obviously, want to die of it. We do prefer death in the struggle to life under cancer’s untenable rule. The enemy is not pain or even death, which will come for us in any eventuality. The enemy is cancer, and we want it defeated and destroyed…better that a few fall in the storming of the bastion, than no storming be attempted.”

Patients may also find meaning and value knowing that they are providing data that may someday benefit someone else.

**Reasonable hope**

While the odds of a clinically important anti-tumor response are low, they are not zero. The perceived hope is not a false hope but the best hope for life that is available. Denying the possibility of therapeutic benefit from early phase cancer trials is untrue. In some cases, eg, imatinib mesylate (Gleevec), there have been long lasting and clinically meaningful responses. On the basis of phase 1 data, the drug was approved by the Federal Drug Administration. In rare cases there have been cures on phase 1 trials. Many patients with testicular cancer were cured in the Phase 1 trials of platinum in the 1970s. Indeed, every antineoplastic agent currently approved was first tested in a phase 1 trial. It is important for the oncologist to be realistic and neither overly optimistic nor nihilistic. Patients must understand the risks and benefits of the trial and their alternatives.

**Alternatives**

Another concern is that terminally ill cancer patients who enroll in phase 1 trials may not know about their alternatives, especially palliative care and hospice. Reviews of phase 1 consent forms indicate that almost none mention hospice as an alternative. However, 56% mention palliative or supportive care, and 26% mention relief of symptoms. Indeed, among ‘classic’ phase 1 studies in which a single chemotherapeutic agent that has never
been tried in humans before is assessed for safety, 69% of informed consent documents mention palliative or supportive care, and 42% mention relief of symptoms.

Some patients who participate in phase 1 trials may be fully aware of the availability of palliative care or hospice as alternatives but do not see them as interventions they want at the time of enrollment in phase 1 trials. In as yet unpublished data, Agrawal and colleagues found that 80% of 90 patients participating in phase 1 studies at five centers were aware of hospice and 89% were aware of palliative care as alternatives. However, only 5% ‘seriously considered’ hospice for themselves and 9% ‘seriously considered’ palliative care as an alternative for themselves. The problem is not awareness of these options; rather it is that people who enroll in phase 1 oncology trials do not want these interventions at this time in the course of their illness.

In part, this finding underscores the misperception that palliative care is end-of-life care as opposed to a component of ‘optimal’ cancer care—whether curative, palliative or experimental in its intent. It is important that patients do not suffer needlessly and palliative care should be part of both control and intervention arms in a clinical trial. The potential of palliative care to manage adverse effects may even allow higher doses of the new agent in phase 1 trials.

**Adverse effects of phase 1 agents**

A full understanding of the risks and benefits of participation in a clinical trial is an essential component of informed consent. For phase 1 trials, the goal of the study to find out at what dose adverse effects occur should be clear to the potential subject.

At the same time, it is also important to recognize that in the last decade or so the nature of early phase oncology research has changed. Vaccines, anti-angiogenesis factors, immunological agents, protein kinase inhibitors, as well as other agents have been introduced into the anti-tumor armamentarium. Research with these agents account for approximately 40-50% of all phase 1 trials. This is important because, compared to traditional chemotherapeutic agents, many of these agents have fewer or no adverse effects, and no maximum tolerated dose is encountered in the early phase studies. Thus, with many newer agents the risk profile may be smaller, enhancing the risk-benefit ratio for patients with advanced disease.

**Research on palliative Interventions**

Research on palliative interventions presents a new area of clinical research. With the development of new interventions to treat symptoms and side effects, clinical research is required on these interventions. For the most part, clinical trial design applies for palliative care agents in the same way as for other agents. The standard of care clinical trial arm should use full palliative therapies, and the new intervention should add or replace one of those in the clinical trial arm.

Patients with refractory symptoms may enroll in a phase 1 trial rather than resigning to uncontrolled suffering or choosing terminal sedation. To be sure patients are refractory to
palliative interventions, and not just poorly managed, it may be important to require assessment by a pain and palliative care service prior to enrollment in a clinical trial. Once an intervention is proven safe and to have efficacy, trying it as a supplement or substitute for other palliative options can be ethical.

Outcome measures are challenging since outcomes are subjective in many instances of palliative care and patients may have reduced awareness. However, progress is being made in this area, with improved quality of life assessments for this population. Further challenges are presented by the often short life span of the patient population so prospective studies are difficult. However, progress is being made in this area too. Oncologists will want to remain alert to palliative care clinical trials that may be available to their patients.

**Opportunities in clinical trials**

What do these data mean for the oncologist and the cancer care team who are working with patients with advancing cancer that are not responding to conventional therapies?

**Ensure that everyone knows that a clinical trial is an option:** As part of disclosing reasonable alternatives in a truly informed consent process, let every patient know that the existing clinical trials, including phase 1 trials, are options. At this time, provide a brief overview. You do not need to discuss the details.

**Expect that only a few patients will inquire about a phase 1 trial:** Phase 1 trials will probably appeal only to the ‘fighters’ or ‘risk takers.’

**Explain what is known; what is not known:** For the patient who expresses an interest, explain the purpose of the trial, including:

- The experimental nature of the study.
- The potential for the trial to benefit the patient (close to zero in phase 1 trials).
- The fact that in phase 1 trials we do not know the risk of adverse events, and that the trial is designed to establish the risk. Explain clearly that some interventions may have few adverse effects.
- Estimate the burden for the patient and family to participate in the trial.

If the patient remains interested, a full informed consent discussion is the next step.

**Patient enrollment and conflicts of interest**

Oncologists, like other clinicians, sometimes engage both in clinical practice and in research. It is possible that motivations to enroll patients in clinical trials may be driven by incentives - financial, career advancement or aspirations to advance research - that go beyond the patient’s interests. To protect against perceptions of or actual coercion, oncologists should be clear about their role when they discuss the trial with their patients.
This may take special care since patients are often emotionally vulnerable and easily swayed because of their illness circumstances.

The patient’s clinician should keep the obligations of his or her clinical role rather than investigator role paramount: in addition, clinicians should enroll patients in a trial only if enrollment meets criteria of free informed consent. The patient should also know what the clinician’s role in the trial is – whether little acquainted colleague of the investigator or a participating investigator. Reassurances that non-participation in a trial will not adversely affect care must be real and credible, especially if the clinician is very involved in the study.

### Discussing phase 1 trials

The 7-Step Protocol, adapted from ‘How To Break Bad News: A Guide For Health Care Professionals’ by Robert Buckman, and also known by its acronym, SPIKES, can be modified to provide a structure to discuss phase 1 clinical trials. The adaptation is illustrated here for discussion of a phase 1 trial.

**SPIKES+**

**7-step protocol to discuss clinical trials**

1. **Setting.** Getting started.
   - 1. Set the stage.

2. **Perception.** What does the patient know?
   - 2. Determine what the patient/family knows.

3. **Invitation.** How much does the patient want to know?
   - 3. How much does the patient want to know? Sufficient desire for information to meet informed consent standards is necessary.

4. **Knowledge.** Sharing the information.
   - 4. Discuss the patient’s situation and the phase 1 clinical trial; information sharing must meet informed consent standards.

5. **Emotion.** Responding to the patient and family feelings.
   - 5. Respond to emotions.

6. **Subsequent.** Planning and follow-up.
   - 6. Plan next steps and follow up.

7. **Review.** Reassess and revise periodically.
   - 7. Review and revise periodically.

The first 3 steps deal with preparatory activities, some of which could be completed before the session at which the physician actually discusses the trial. At the fourth step,
the news is delivered. The following 2 steps permit the physician to respond to the patient’s reactions and constructively plan for follow-up.

**Step 1: Set the stage**

Before initiating a discussion about a phase 1 clinical trial, familiarize yourself with:

- The details of the patient’s diagnosis, history and prognosis.
- The details of the protocol, the known facts about the study medication and its potential for benefit, risk of adverse events, and burden to the patient and family to participate in the trial.
- Alternative treatment options.

Have written information about the trial, including the consent, available for the patient and family to take away and read.

Determine who else the patient would like to have present for the discussion. This might include family members, significant other(s), or other health professionals or caregivers who are involved with the patient’s care.

Find a quiet place for the discussion. Ensure everyone is comfortable. To minimize interruptions, turn off mobile phones and pagers, or give them to someone outside the meeting.

**Step 2: Determine what the patient and family know**

Start the discussion by establishing what the patient and family know about the patient’s diagnosis and prognosis, their goals of care and expectations about treatment. Ascertain what else they are hoping to achieve in the time that remains (particularly if prognosis is limited). Ask what they know about phase 1 clinical trials. Questions might include:

- What do you understand about your illness?
- How would you describe your medical situation?
- What do you expect from your future?
- What do you hope for from future treatment?
- Tell me what you know about clinical trials?
- Tell me what you know about phase 1 clinical trials?
- What do you expect from a phase 1 clinical trial?

**Step 3: How much does the patient want to know?**

Next, establish how much and what each patient wants to know; who is a ‘fighter,’ and who is not. Everyone handles information differently. Some patients want to hear all of the details related to toxicity and expectations for the future, while others prefer
generalities. If there is critical information that needs to be communicated during the trial, establish to whom information should be given.

As in any situation where information is to be shared and decisions taken, there are ethnic and cultural differences in the preferred handling of information. While knowledge of such differences is useful as a background, global conclusions about them rarely help with decision making for an individual. Ask a patient about general preferences for handling of medical information and decision making early, before significant information needs to be shared. This will help the clinician to avoid making a misstep. Possible questions include:

- Would you like me to tell you the full details of what you might expect? From the experimental drug? For your future?
- If not, is there somebody else you would like me to talk to?

Use the responses to these queries to assess the potential to complete informed consent discussions. In order to comply with standards for informed consent, the patient must be comfortable with receiving all information relevant to that process, and with making his or her rational, autonomous decisions.

If the patient wants decisions to be made by another person, proceed with participation in a clinical trial only with great caution. It may be possible to establish a Durable Power of Attorney for Health Care to make decisions if the patient strongly wants to participate yet not handle information. However, counselling against participation for such a patient may be wiser.

**Step 4: Discuss the patient’s situation and the phase 1 clinical trial**

When the patient and those present are ready, review the facts about the patient’s situation – the diagnoses and prognosis, experience with anti-cancer therapy, and the potential for any other anti-cancer therapy to be of any benefit.

Deliver information in a straightforward manner about the intent of phase 1 trials, the scientific background of the investigational agent, its potential toxicity and the burden that the patient and family will face to participate in the trial. Don’t minimize the potential toxicity or the time commitment to participate in the trial. Speak in simple terms first. Avoid using medical jargon. Pause frequently. Check for understanding. Encourage questions. Evolve to more complex concepts once you verify understanding.

Ensure that everyone who enrolls in a phase 1 trials understands that s/he is taking a risk of side effects with a low chance of personal benefit.

Data suggests most patients who enroll in phase 1 studies already do understand this— they have hope while still being realistic. However, oncologists should reinforce this point while not being nihilistic, probably by saying something like:
• We are all hoping for the best and that your tumor responds to the experimental drug (or agent), but we also need to recognize that you very well may not benefit at all. Since this is the first time the drug is being used in people this is a long shot, not even close to a guarantee.

Emphasize that participation, or not, will not compromise standard care. It is very important for patients and families to know the alternatives available to them. Emphasize, that, whatever the patient’s choice:

• The oncologist and the cancer care team will not abandon them.

• Enrollment is not mutually exclusive with treating pain, nausea, or any other appropriate palliative care.9

Too often both oncologists and patients seem to think that palliative care is an alternative to chemotherapy or enrollment in clinical research trials. It does not have to be an either/or choice: palliative care or anti-cancer treatment.

• Let the patient know that the clinical trial team personnel and you are committed to providing both palliative care and anti-cancer treatment simultaneously.

• Explain that the study will use anti-cancer therapy to kill tumor cells, and use palliative care to help the patient ‘eat well, sleep well, minimize stress, maintain function, self esteem and quality of life’ while on a phase 1 trial. Almost all clinical research studies, including phase 1 trials permit both therapeutic approaches simultaneously. It is the very rare clinical trial that contains exclusion of some palliative care options, usually to avoid specific drug-drug interactions, and none contain blanket exclusions of all palliative interventions.

• Emphasize that utilizing palliative care is not ‘giving up’ or implying that there is ‘nothing else to do.’ Let the patient know that it may even help to minimize the impact of adverse events from trial medications and facilitate a more expeditious and successful outcome for the trial.

With this perspective, oncologists should commit to reassure patients considering phase 1 trials, saying something like:

• We are also going to use standard interventions to relieve your symptoms and support you. We know this doesn’t interfere with getting the full effect of the experimental drug. We will try to eliminate suffering while still trying to beat your cancer.

Review the consent form with the patient and family. Offer them time to review the form and to ask you or study personnel any questions.

Again, reassure the patient and family that:

• You will not abandon them.

• They will continue to have access to comprehensive cancer care no matter what their choice.
• The patient can withdraw from the clinical trial at any time.

**Step 5: Respond to emotions**

Respond calmly and with understanding to any emotions the patient and family may express. To the question, ‘Are you using me as a guinea pig?’ you might respond with language like the following:

• Well, that’s one way to put it. Another is that we need people like you to help us develop the drugs of the future—just as other patients participated in past clinical trials so you could benefit from the treatment you’ve already had. It is the case that a very small number of patients in these trials have improvements in their cancer. It’s important that you understand that the main purpose of the trial is to see how human beings tolerate the drug.

To the exclamation, ‘I’m going to go through all of this for nothing!’ you might respond as follows:

• It is true that you may receive no personal gain and no improvement in your tumor or prognosis from this treatment. However, we may learn things from this trial that will help other people. It is through clinical trials and the evaluation of new treatments that we have improved the outcome for some cancer patients.

To the concern, ‘I’m going to give up all of the good time I have left,’ you might respond:

• There is a loss of personal time associated with participation in this study. You might spend your time differently if you were not participating in this study. Some patients, when they look back, feel like they would have rather gone on a trip, or spent more time with their kids, than coming to the doctor’s office.

If participation in a clinical trial will jeopardize the patient’s chance to complete life goals, eg, if s/he is approaching the end of life and has little time left to complete important relational work or other tasks, the trial may not be appropriate for the patient.

**Step 6: Plan next steps and follow up**

Establish a plan for the next steps. For the patient who consents to participate in a clinical trial, explain plans for any needed evaluations. Review and provide a written schedule of planned tests, office visits, and treatment. Introduce the patient and family to study personnel that may interact with the patient. Be sure the patient knows how to access supportive care. Reassure the patient that you will continue to be available.

For the patient who declines to participate in a phase 1 trial, discuss alternate treatment choices, symptom management, and planned follow-up. Reassure the patient that you will continue to be available for questions and follow-up. Establish the time for the next appointment.
Step 7: Review and revise periodically

As people can change their goals of care and treatment and life priorities, review their understanding of the clinical trial and how it is going periodically. Make sure they continue to understand the intent of the clinical trial. Answer any questions. It is always comforting for patients and families to know that the plan can change at any time.

Summary

Participation in cancer clinical trials, especially phase 1 trials for advanced disease, is low. The reasons for low enrollment include the lack of appropriate trials, restrictive enrollment criteria, physicians’ failure to offer the trials, and patient refusal to participate. Patients who choose to enroll in phase 1 studies usually recognize the small potential for personal gain, but as ‘fighters,’ hope for a response from the treatment. Oncologists need to present clinical trial options, follow the steps for good communication and informed consent, and integrate symptom management into cancer care.

Key take-home points

1. Participation in adult clinical trials is low.
2. Use a modification of the 7-step approach, particularly when learning this skill, to present phase 1 clinical trials.

Step 1: Set the stage

3. Familiarize yourself with the trial and prepare what you are going to say.
4. Determine who else should be present.

Step 2: Determine what the patient and family know

5. Establish what the patient (and family) knows about the patient’s disease status.
   Establish what the patient expects from treatment and his/her understanding of clinical trials / phase 1 studies.

Step 3: How much does the patient want to know?

6. People handle information differently.
7. Find out how much the patient wants to receive.
8. Ensure that informed consent standards can be met.

Step 4: Discuss the patient’s situation and the phase 1 clinical trial

9. Deliver the information in a straightforward manner. Avoid jargon and encourage questions.
10. Adhere to informed consent requirements.

Step 5: Respond to emotions
11. Respond calmly to patients’ concerns about clinical trial participation.

**Step 6: Plan next steps and follow up**

12. Establish a plan for next steps.

**Step 7: Review and revise periodically**

13. Check understanding and goals of care periodically. Ensure comfort to continue participation in the trial

**Pearls**

1. Give enough time for the information to soak in.
2. Ask for the patient to repeat back what they’ve understood.
3. Patients may take more risks and want to enter a clinical trial, even a phase 1 trial, when established therapeutic options have run out.
4. ‘Fighters’ may hope for amelioration of their cancer even when the odds are against them if this small chance is the best they have. It can be rational to enter a trial and not a misconception on their part.

**Pitfalls**

1. Letting other considerations (promotion, publications, enthusiasm, limited time) influence a balanced presentation of risks and benefits. This would be a mistake.
2. To imagine that all participants in phase 1 studies are doing so because of a therapeutic misconception. This would be a mistake.
3. Belief that research on palliative care is precluded on ethical grounds. This would be misguided. Palliative care research is necessary and can be done in full compliance with ethical requirements.
4. Failure to alert patients to the option of participation in a clinical trial. This deprives the patient of important options and slows the progress of research.

**References**


   A summary of the most recent data on cancer incidence, mortality and survival using incidence data from the National Cancer Institute and mortality data from the National Center for Health Statistics.


   To measure the quality of understanding among participants in clinical trials of cancer therapies, to identify correlates of increased understanding, and to assess providers' beliefs about clinical research. A standard questionnaire was administered to 287 adult patients with cancer who had recently enrolled in a clinical trial. The provider who obtained each patient's consent was also surveyed. Only 46% of
providers recognized that the main reason for clinical trials is benefit to future patients. Frequent misconceptions about cancer clinical trials among trial participants are identified and discussed. Efforts to educate providers and participants about the underlying goals of clinical trials are needed,


To describe and compare the perceptions of cancer patients and their physicians regarding phase 1 clinical trials, both completed questionnaires with domains including perceptions of potential benefit and harm from treatment (experimental and standard), relative value of quality and length of life, and perceived content of patient-physician consultations. Cancer patients offered phase 1 trial participation have expectations for treatment benefit that exceed those of their physicians. The discordant perceptions of patients and physicians may possibly be explained by patient optimism and confidence; however, the discrepancies in reports of consultation content raise the possibility that communication in this context is suboptimal.


To describe the expectations and experiences of patients entering phase 1 clinical trials, a descriptive, exploratory, prospective study was undertaken. Interviews using structured entry and exit questionnaires evaluated expectations and experiences of patients in phase 1 clinical trials. Patients expected slightly increased support from family members and received more support than expected. Patients’ expectations for tumor response and increased communication with their physician were not met. The implications for nursing practice are discussed.


This Perspective includes an essay on modifying phase 1 clinical trials, written by George Zimmer, a cancer patient who participated in the phase 1 clinical trial program at the University of Chicago, and a professor of English. A commentary on his essay is included.


To evaluate the written description of direct benefit as well as risk, all consent forms for 1999 phase 1 cancer trials were compiled from 80 percent of the National Cancer Institute-designated cancer centers and from six of eight large pharmaceutical developers of anticancer drugs. Consent forms for phase 1 oncology studies almost never promise direct benefit, rarely mention cure, and usually communicate the seriousness and unpredictability of risk. The consent forms are unlikely to be the primary source of misunderstanding by subjects in phase 1 oncology trials.


A protocol for disclosing unfavorable information-"breaking bad news"-to cancer patients about their illness is presented. Directions for continuing assessment of the protocol are suggested.

This paper focuses attention on and offers an analysis of how to meet the needs of participants in clinical research who are terminally ill. Two important tasks are reconciled: providing optimal end-of-life care and conducting clinical research. The inherent tension between the goals of medicine and the goals of science are examined. Suggestions to address this tension are presented.